10.05
0.35 (3.61%)
| Penutupan Terdahulu | 9.70 |
| Buka | 9.69 |
| Jumlah Dagangan | 108,176 |
| Purata Dagangan (3B) | 207,290 |
| Modal Pasaran | 366,788,832 |
| Harga / Buku (P/B) | 1.16 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 Mar 2025 |
| EPS Cair (TTM) | -3.78 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.48% |
| Nisbah Semasa (MRQ) | 35.34 |
| Aliran Tunai Operasi (OCF TTM) | -64.83 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -44.47 M |
| Pulangan Atas Aset (ROA TTM) | -22.07% |
| Pulangan Atas Ekuiti (ROE TTM) | -35.09% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Rapport Therapeutics, Inc. | Bercampur | - |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.83 |
|
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 6.59% |
| % Dimiliki oleh Institusi | 100.74% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Trv Gp V, Llc | 31 Dec 2024 | 7,135,233 |
| Trv Gp Vi, Llc | 31 Dec 2024 | 969,218 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 21 Mar 2025 | Pengumuman | Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting |
| 11 Mar 2025 | Pengumuman | Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
| 03 Mar 2025 | Pengumuman | Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development |
| 24 Feb 2025 | Pengumuman | Rapport Therapeutics to Participate in Upcoming Investor Conferences |
| 09 Jan 2025 | Pengumuman | Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |